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Abstract 
Background: Rheumatoid arthritis (RA) and osteoarthritis (OA) are widespread rheumatic diseases characterized by 
persistent inflammation and joint destruction. Hydrogen sulfide (H2S) is an endogenous gas with important 
physiologic functions in the brain, vasculature and other organs. Recent studies have found H2S to be a mediator in 
inflammatory joint diseases. 
Objective: This review summarizes the recent literature in this area highlighting relevant developments. 
Conclusions: Several authors have found that H2S exhibited anti-inflammatory, anti-catabolic and/or anti-oxidant 
effects in rodent models of acute arthritis and in in vitro models using human synoviocytes and articular chondrocytes 
from RA and OA tissues. The earliest studies used fast-dissolving salts, such as NaSH, but GYY4137, which 
produces H2S more physiologically, shortly appeared. More recently still, new H2S-forming compounds that target 
mitochondria have been synthesized. These compounds open exciting opportunities for investigating the role of H2S 
in cell bioenergetics, typically altered in arthritides. Positive results have also been obtained when H2S is 
administered as a sulphurous water bath, an option meriting further study. These findings suggest that exogenous 
supplementation of H2S may provide a viable therapeutic option for these diseases, particularly in OA. 
Keywords: Inflammatory joint diseases; hydrogen sulfide; mitochondria; osteoarthritis; rheumatoid arthritis; 
sulphurous spring waters  
 
 
 
  
1. INTRODUCTION  
Rheumatoid arthritis (RA) and osteoarthritis (OA) represent two of the most common arthritides in the 
developed world. RA, a chronic inflammatory autoimmune disease affecting diarthrodial joints, is 
characterized by joint swelling, tenderness and eventual destruction of synovial joints, leading to 
functional impairment and shortened life expectancy. While the etiology of RA is unknown, one 
hypothesis is that the disease ensues from an environmental trigger in a genetically predisposed individual 
[1, 2]. From disease onset, an inflammatory infiltrate' of mononuclear cells exists in the synovial 
membrane, followed shortly by synovitis. In RA, the two types of cells, macrophage-like synoviocytes 
(MLS) and fibroblast-like synoviocytes (FLS), contained in the synovial intimal lining become activated. 
MLS produce large amounts of tumor necrosis factor-a (TNF), interleukin (IL)-lβ, granuloeyte-
macrophage colony stimulating factor (GM-CSF) and chemokines, such as IL-8. These factors further 
stimulate the FLS to become the primary source of mediators contributing to joint destruction. Important 
among these mediators are matrix metalloproteinases (MMPs) , particularly collagenases, stromelysins 
and gelatinases, all of which are responsible for joint structural damage, other molecules that enhance the 
inflammatory response (IL-6, cyclooxygenase (COX)-2, prostaglandin (PG) E2 or IL-8) and mediators 
that increase vascular permeability and facilitate angiogenesis [vascular cell adhesion molecule (VCAM)-
l, vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF)]. The interactions 
between MLS and FLS involve complex cytokine networks that perpetuate synovitis, TNF-α, IL-1β and 
IL-6 are key cytokines causing inflammation in RA, with TNF-α having the dominant role because it is a 
potent paracrine inducer of other inflammatory cytokines [3,4]. 
 
In contrast, OA is characterized by the progressive loss of articular cartilage resulting from an 
imbalance of the catabolic and anabolic processes in chondrocytes. OA characteristically has a significant 
chronic inflammatory state [5]. Local inflammatory molecules contribute to progression of the disease in 
the early stages, finally resulting in chronic inflammation. These local inflammatory molecules include 
IL-lβ, TNF-α, IL-6, nitric oxide (NO) and PGE2. Particularly in OA, IL-1β is a key pro-inflammatory 
factor (Reviewed in [6-8]). 
 
While there are two receptors for IL-1β, IL-1RI and IL-1RII, only IL-1RI can transduce the IL-lβ 
signal [9].  
 
The articular chondrocytes (AC) and FLS of OA patients express high levels of IL-1RI (10, 11] and 
increased numbers of chondrocytes synthesizing IL-lβ and TNF-α occur in OA cartilage [12]. When IL-lβ 
binds to IL-1RI, several signalling and transcriptional pathways, such as nuclear translocation of nuclear 
factor kappa-light-chain-enhancer of activated B cells (NFκB), activation of protein kinase (PK) C, p38, 
extracellular signal regulated kinases (ERK) 1/2 or c- Jun N-terminal kinases (JNK) are initiated [13, 14]. 
Therefore, in OA, IL-lβ is responsible for the inhibition of anabolism by the reduction in the production 
of collagen type II and aggrecan and the induction of catabolism by the upregulation of MMPs and 
aggrecanases in ACs [15]. IL-lβ also participates in the upregulation of PGE2 synthesis enzymes, COX-2 
and microsomal prostaglandin E synthase-1 (PTGES), which leads to increased PGE2 production [16, 17].  
 
In both RA and OA, reactive nitrogen species (RNS) and oxygen species (ROS) are also important 
players involved in inflammation. NO, peroxynitrite, H2O2 or O2 cause deleterious effects in cells, 
including oxidative damage to proteins, membranes and DNA and activation of the cells apoptotic 
pathways. NO contributes to the enhancement of the activation and production of MMPs, the inhibition of 
synthesis of anabolic molecules [18] and the promotion of chondrocyte apoptosis in both RA and OA 
[19]. During energy metabolism, the mitochondrial respiratory chain is the main source of ROS [20]. 
Evidence that mitochondrial dysfunction contributes to the pathophysiology of inflammatory joint 
diseases [21, 22] and to a wide range of other pathologies [23] is accumulating.  
 
Hydrogen sulfide (H2S), a gas detectable by its characteristic odor of rotten eggs, is very toxic in high 
concentrations. H2S exerts its toxicity by the inhibition of cytochrome C oxidase and reduction of ATP 
production [24]. Early studies were concerned with its environmental toxic effects and with measurement 
techniques for the detection and prevention of the risks associated with human exposure [25]. We have 
since learned that H2S is an endogenous gasotransmitter capable of penetrating cell membranes without a 
specific transporter. H2S is produced in most tissues in considerable levels and participates in many 
physiologic and pathologic events (reviewed elsewhere [26-29]). Evidence is mounting that H2S plays an 
important role in inflammation [30, 31] and that exogenous supplementation of H2S could be of 
therapeutic value in several diseases [29]. This review ad- dresses the relevance of H2S supplementation 
in the context of acute and chronic inflammation as it relates to RA and OA, including current methods 
for H2S exogenous administration, as available in current literature.  
2. HYDROGEN SULFIDE SOURCES  
2.1. Endogenous Synthesis of Hydrogen Sulfide  
Endogenous H2S is chiefly produced by three enzymes, cystathionine β-synthase (CBS, EC 4.2.1.22), 
cystathonine γ-lyase (CTH, EC 4.4.1.1) and 3-mercaptopyruvate sulfurtransferase (MPST, EC 2.8.1.2). 
These enzymes, which utilize cystathionine, homocysteine or L-cysteine to produce hydrogen sulfide, are 
found in various tissues and their expressíon and distribution are tissue specific [28, 32, 33]. CBS is the 
predominant enzyme in the brain and heart and CTH is mainly expressed in the liver, kidney and 
intestine, and by vascular smooth muscle cells [32]. MPST has been reported in the brain, liver, kidney 
and heart [33]. CBS and CTH are exclusively cytosolic enzymes, while MPST is found both in the 
cytosol and mitochondria of cells [33].  
2.2. Endogenous H2S and Rheumatic Diseases  
Articular tissues also express enzymes associated with H2S synthesis. A recent publication reports that 
chondrocyte- like cells (chondrogenically differentiated mesenchymal pro- genitor cells, CH-MPCs) and 
primary human (h) Aes express both CBS and CTH, and that CTH is induced in both cell types by IL-lβ, 
TNF-α, IL-6 or lipopolysaccharide (LPS) treatment [34]. Our group bas found these three enzymes at 
mRNA and protein levels in cartilage, synovial membrane and subchondral bone from OA and normal 
patients [35]. Other studies have shown that synovial fluid (SF) H2S concentrations in patients with RA 
[36, 37] or gout [37] were significantly higher than those in paired H2S plasma values and those in the SF 
of age-matched OA patients. In addition, one investigator reported that SF H2S levels of RA patients 
correlated with the disease activity score in 28 joints and tender joint count [37].  
 
This same study also reported that plasma H2S levels in RA and gout did not differ significantly from 
those of healthy controls, while those of OA patients were significantly higher [37]. In contrast, 
Whiteman et al. [36] and similar studies by our group did not reveal any differences in H2S concentration 
in serum between OA patients and healthy controls. On the contrary, we have preliminary evidence that 
indicates that H2S biosynthesis in OA joints might be reduced [35].  
 
One hypothesis recently promulgated states that when H2S is increased in inflammatory diseases, it 
represents an endogenous compensatory mechanism by cells attempting to overcome inflammation, 
indicating that H2S may play an anti-inflammatory role [30, 38-40], although further studies are needed to 
test this hypothesis.  
2.3. Exogenous Administration of H2S  
Many of the early studies investigating the inflammatory role of H2S in in vivo models or in cells in 
vitro used fast-dissolving salts, such as Na2S, NaSH or Lawesson's reagent (LR), to generate and deliver 
H2S. These reagents produce an immediate burst of H2S that lasts a few seconds. However, this brief 
concentration is likely not a good model for in vivo physiologic H2S synthesis, which may occur in 
smaller quantities and much more slowly. In 2008, GYY4137 (morpholin-4-ium-4-methoxyphenyl 
(morpholino) phosphino-dithioate), a new type of H2S-delivering compound, was synthesized [41]. This 
compound slowly produces H2S both in vitro and in vivo. Using an endotoxic shock rat model and also in 
RAW264. 7 macrophages, GYY 413 7 exhibited anti-inflammatory effects [42]. When GYY4137 was 
administered to conscious rats 1 or 2 h prior to LPS treatment, the ensuing rise in plasma pro-
inflammatory cytokines (TNF-α, IL-1β and IL-6) and lung myeloperoxidase (MPO) activity was 
decreased, while plasma concentration of the anti-inflammatory cytokine IL-1O was increased. In macro- 
phages, GYY 413 7 reduced NFKB activation, the expression of the inducible form of NO synthase 
(iNOS) and COX-2, as well as the generation of PGE2 and NO-derived nitrites/nitrates [42].  
 
A more recent series of H2S-delivering compounds that target mitochondria has been synthesized. 
These compounds contain a mitochondria-targeting moiety (triphenylphosphonium) that accumulates in 
the mitochondria [43] coupled to an H2S-releasing moiety (dithiolethione or thiohydroxybenzamide). The 
effect of AP39 [(10-oxo-10-(4-(3-thioxo-3H- 1,2-dithiol-5yl)phenoxy)decyl)triphenyl-phosphonium 
bromide], one of these compounds, was recently tested on bioenergetics, viability and mitochondrial 
DNA integrity of resting cells and during oxidative stress in bEnd.3 murine microvascular endothelial 
cells [44]; the results demonstrated anti-oxidant and cytoprotective effects during oxidative stress. These 
compounds also seem to be more potent than other H2S-forming compounds; the range of concentrations 
needed to exert beneficial effects being 30-100 nM, appreciably lower than those reported for NaSH, LR, 
Na2S or GYY4137 [44]. These new compounds are novel and useful research tools to investigate the 
impact of H2S on cell bioenergetics and are likely to produce important information about the etiology of 
inflammatory joint diseases, possibly offering new therapeutic approaches.  
 
Finally, we should mention that the pharmacological addition of H2S-fonning reagents or drugs is not 
the only way to supply H2S exogenously. Beneficial effects, in particular, anti-inflammatory and anti-
oxidant effects, on patients with chronic lung disease [45, 46], chronic rhinosinusitis [47], allergic 
disorders [48] and rheumatologic diseases [49] when H2S is administered in the form of sulphurous 
mineral water have been reported.  
3. H2S AND ACUTE AND CHRONIC ARTHRITIDES  
To date, most studies on the inflammatory effects of H2S used models of acute inflammation. Some of 
these studies have found exogenous H2S treatment to exert anti- inflammatory effects in such classic 
inflammation models as gastrointestinal inflammation [50] or endotoxic shock [42], although 
contradictory reports can be found in recent literature. Studies supporting the hypothesis that H2S may be 
protective or beneficial that investigate the molecular mechanisms involved in rheumatic inflammatory 
joint pathologies are relatively recent (for a summary see Table 1).  
  
Table 1. Summary of the literature concerning the effects of H2S forming compounds on intlammatory joint disease in vivo or in  
vitro models.  
Reference Pathology 
Animal Model/ 
Cellular Type 
Stimuli 
H2S Compound  
and 
Concentration 
Main Results 
      
Sieghart el al. 
[51] 
OA FLS IL-1β NaSH  
(up to 1 mM, 
20 min) 
Reduced spontaneous and IL-1β 
induced secretion of IL-6, IL-8 and 
RANTES. Inhibited the formation 
of hyperplastic lining layer in FLS 
micromasses. 
Burguera el 
al. 
 [52] 
OA hACs IL-1β or LPS NaSH and  
OYY4137 (50-
1000 μM, 48 h) 
Reduced MMP-3 mRNA and 
protein. 200 μM OYY4137 
reduced LPS-induced 
mitochondrial ROS. No effect on 
SOD2 or CAT mRNA. 
Burguera el 
al.  
[53] 
OA hACs IL-1β  
(5 ng/ml, 48 h) 
NaSH and  
OYY4137 (50-
1000 μ1M, 
48h) 
Reduced NO and iNOS (mRNA 
and protein), POE2 levels, COX·2 
and PTOES mRNA; no effect on 
COX-1. Reduced IL-6 and 
MMP13 levels and mRNA. 
Ha et al.  
[54] 
OA hACs IL-1β 
(10 ng/mi, 2 h) 
NaSH  
(0.06-1.5 mM, 
30 min 
pretreatment) 
Reduced NO and iNOS (mRNA 
and protein), POE2 levels, COX-2 
mRNA; MMP13 levels and 
mRNA, up to 0.6 mM. Best result 
with 0.3mM NaSH. 
Kloesch el al. 
[55] 
RA and OA FLS - NaSH  
(up to 1 mM, 
20 min) 
NaSH >0.5 mM, 20 min increased 
IL-6, IL-8, COX-2 in OA and RA-
FLS, and increased MMP3 mRNA 
in RA-FLS. But it also reduced 
MMP-14 and MMP-2 in RA-FLS. 
Kloesch el al. 
 [56] 
RA FLS IL-1β 
(5 ng/ml, 1 h) 
NaSH  
(0.03-1.0 mM) 
NaSH short-term exposure (<0.125 
mM, 60 min) reduced constitutive 
and IL-1β-induced IL-6. NaSH 
long-term exposure (0.125 mM, 6 
h) increased IL-6. 
Kloesch el al. 
 [57] 
- Chondrocyte cell 
line C28/I2 
IL-1β 
(5 ng/ml, 1 h) 
NaSH (up to 1 
mM) 
NaSH 0.125 mM, 30 min or 1 
mM, 15 min reduced IL-1β-
induced IL-6 and IL-8. 
Stulhmeier et 
al.  
[58] 
RA FLS - NaSH  
0.05-5 mM 
NaSH 2mM, 45 min increased 
HO-1 and HSP70 mRNA and 
protein levels. But TNF, IL-8, IL-
1β and COX-2 gene expression 
and protein levels were also 
elevated. 
Fox et al.  
[34] 
Normal Chondrogenically 
differentiated MPCs 
and hACs 
SIN-1 
H2O2 
4-HNE 
GVY4137 
200 and 500 
μM 
Reduced SIN·1, H2O2 or 4-HNE 
induced cell death, mitochondrial 
toxicity (collapse of mitochondrial 
membrane potential), oxidant 
stress induced cellular ATP 
depletion and cytoplasm 
accumulation of cytochrome C. 
Li et al.  
[40] 
Normal hFLS and hCHs LPS GYY4137 Reduced NO, POE2, TNF-α and 
IL-6, also the catalytic activities of 
iNOS, COX-2. 
Andruski et 
al. 
 [59] 
Acute knee 
inflammation 
C57b1/6 mice Kaolin/carrageenan 
intraarticular 
injection 
Na2S 
10, 30 or 50 
μM 
H2S reduced leukocyte adherence 
and increased leukocyte velocity, 
suggesting of an anti-inflammatory 
effect, but had no influence on 
pain. 
      
 
  
 
 
 
Fig. (1). Summary of the effects of the exogenous administration of hydrogen sulfide (H2S) in osteoarthritis (OA) and rheumatoid 
arthritis (RA) using in vitro and in vivo models. The key pro-inflammatory cytokines are tumor necrosis factor-α (TNF-α) in RA and 
interleukin-1β (IL-1β) in OA. In RA, macrophage-like synoviocytes produce large amounts of TNF-α and IL-1β, and chemokines, 
such as IL-8. These activate fibroblast-like synoviocytes, which become the primary source of mediators that contribute to joint 
destruction. These mediators include matrix metalloproteinases (MMPs), IL-6, cyclooxygenase (COX-2), prostaglandin (PG) E2 and 
other mediators that increase vascular permeability and facilitate angiogenesis. In OA, IL-1β is responsible for an increase in the 
production of lL-6, nitric oxide (NO), PGE2 and also MMPs. Reactive nitrogen (RNS) and oxygen species (ROS), are also among 
the critical players involved in inflammation in both RA and OA. Virtually all reports on the administration of exogenous H2S, in 
various forms, using in vitro and in vivo models and human trials related to OA, provide evidence of beneficial effects, including the 
reduction of some oxidation, inflammation and markers of catabolism mentioned above. On the other hand, most published studies 
using RA models show exacerbation of inflammation symptoms which, collectively, do not support the idea that H2S 
supplementation might be beneficial to RA patients. 
3.1. H2S and In Vitro Models of Chronic inflammation  
Several groups, including ours, have used in vitro models with FLS or ACs from RA or OA patients 
to shed light on the role of H2S in these two rheumatic diseases. To evaluate its effects, these studies have 
typically used IL-1β or other pro-inflammatory stimuli, including LPS, to produce an inflammatory 
environment in vitro and NaSH or GYY4137 as H2S-fonning reagents. For a graphic representation of the 
effects of H2S on OA and RA cells using in vitro models (Fig.1).  
3.1.1. Hydrogen Sulfide and OA  
Studies by our group [52, 53] and others [54] demonstrated the in vitro anti-inflammatory and anti-
catabolic effects of NaSH and GYY4137 on OA hACs. Our results showed that co-stimulation of these 
cells for 48 h with IL-1β (5 ng/ml) and either H2S generator led to significant reductions in NO, PGE2, IL-
6, MMP3 and MMP13 levels. In these stimulated cells, the mRNA expression of relevant genes involved 
in the synthesis of these molecules, including iNOS, COX-2 and PTGES, IL-6, MMP3 and MMP13, was 
also downregulated by the action of H2S. Protein levels of MMP3, MMP13 and iNOS were also reduced 
as demonstrated by immunocytochemistry. After pre-treating OA hACs with NaSH for 30 min prior to 
stimulation with 10 ng/ml of IL-1β for two additional hours, Ha and co-workers [54] found reductions in 
the production of NO and PGE2 and MMP13 proteins by ELISA, as well as reduced mRNA expression of 
iNOS, COX-2 and MMP13. In our studies, there was also a partial reduction of the nuclear translocation 
of NFKB p65 induced by IL-1β treatment [53]. In agreement with this observation, Ha et al. [54] 
pretreated cells with 0.3 mM NaSH prior to a 2 h exposure to 10 ng/ml IL-1β and found that the 
activation of NFKB was inhibited. Table 2 and Fig. (2) provide a summary and a graphical representation, 
respectively, of the signalling and transcription routes that have been implicated in the effects of H2S on 
inflammatory joint cells.  
Table 2. Signaling and transcription routes known to be implicated in the effects of H2S on inflammatory joint cells 
Reference Pathology Celular Type Insult 
H2S Compound 
and Concentration 
Signaling and Transcription Routes 
      
Burguera et 
al. [53] 
OA hACs IL-1β 
(5 ng/ml, 48 
h) 
NaSH and GYY4137 
(50-1000 μM, 45 min) 
Both compounds lead to a partial reduction of 
NFKB p66 translocation to the nucleus. 
Sieghart et 
al. [51,61] 
OA FLS IL-1β 
(10 ng/ml) 
NaSH 
(up to 1 mM, 20 min) 
NaSH reduced IL-1β activation (phosphorylation) 
of several MAPKs (MSK2, MKK6) and GSK-3a/β 
but p38 was not affected. It also increased 
phosphorylation of Akt1/2 by 50-60%. 
Ha et al. [54] OA hACs IL-1β 
(10 ng/ml, 2 
h) 
NaSH 
(0.06-1.5 mM, 30 min 
prerreatrnent) 
Pre-incubation with NaSH (0.3 mM, 30 min) 
reduced phosphorylation of ERK1/2, IKBα and 
NFkB-p65 and inhibited activation of NFkB. 
Kloesch et 
al. [56] 
RA FLS IL-1β 
(5 ng/ml, 1 
h) 
NaSH 
(0.03-1.0 mM) 
NaSH short-term exposure (<0.125 mM, 60 min) 
reduced phosphorylation of ERKI/2, MEK1/2. 
NaSH long-term exposure (0.125 mM, 6 h) 
increased phosphorylation of ERK1/2, MEK1/2 
and p38. 
Kloesch et 
al. [57] 
- Chondrocyte 
cell line C28/I2 
IL-1β NaSH 
(up to 1 mM) 
NaSH 1 mM, 60 min activated MEK/ERK and 
was not able to block the degradation of IkBα nor 
the phosphorylation of NFkB p65. 
Stuhlmeier et 
al. [58] 
RA FLS - NaSH 
0.05-5 mM 
NaSH (2 mM) induction of pro-inflammatory 
genes did not involve NFkB. Rather, it resulted in 
the phosphorylation of ERK, p38 and JNK. 
Activation of COX-2 and IL-1β required the 
activation of p38 and ERK, respectively. 
Kloesch et 
al. [55] 
RA and 
OA 
FLS - NaSH 
(up to l mM) 
NaSH l mM, l h induced the activation of ERK1/2. 
Inhibitors of MAPKs inhibited H2S induced 
ERK1/2 activation. 
Fox et al. 
[34] 
Normal CH-MPC and 
Normal hACs 
SIN-1 
H2O2 
4-HNE 
GYY4137 
200 and 500 μM 
GVY4137 induced an increase in the phos- 
phorylation of Akt in hACs. Results suggested 
that actívatíon of Akt signaling pathway was 
required for H2S-mediated cytoprotectíon 
Li et al. [40] Normal hFLS and hCH LPS GVY4137 Reduced NFkB activation. 
      
 
  
 
 
 
Fig. (2). Schematic representation of the signalling and transcription routes implicated in the effects of the exogenous administration 
of hydrogen sulfide compounds to articular cells. Hydrogen sulfide has been shown to influence several members of the mitogen 
activated protein kinase family (incIuding ERK1/2, MEK1/2, JNK or p38), other serine/threonine protein kinases (Akt1/2, GSK-
3α/β), as well as to interact with the NFkB signalling route. The reported effects varied depending on the cell type studied, the H2S 
forming compound used and its concentration, and the incubation time. Abbreviations: H2S, hydrogen sulfide; FLS, fibroblast-like 
synoviocytes; AC, articular chondrocytes; CH-MPC, chondrogenically differentiated mesenchymal progenitor cells; OA, 
osteoarthritis; RA, rheumatoid arthritis; ERK, extracellular signal regulated kinase; MEK, MAPK/ERK kinase; MSK, mito gen- and 
stress-activated protein kinase; MKK, mitogen-activated protein kinase kinase; Akt, protein kinase B; GSK-3, glycogen synthase 
kinase 3; IkB, nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor; JNK, c-Jun N-terminal kinases; NFkB, 
nuclear factor kappa-light-chain-enhancer of activated B cells. 
However, a different study found that NaSH treatment was detrimental to OA hFLS [55]. NaSH 
concentrations above 0.5 mM applied for 20 min treatments stimulated the express ion of IL-6, IL-8 and 
COX-2 mRNA for as long as 6 h afterward. Nevertheless, further investigations by the same group 
concluded that pre-treatment with NaSH dose- dependently reduced spontaneous, as well as IL-1β-
induced, IL-6, IL-8 and RANTES (regulated on activation, normal T cell expressed and secreted) 
production in OA hFLS, with 1 mM NaSH proving to be the most effective concentration [51]. These 
authors also examined signalling routes by spot blot assay and determined the activation of 26 mitogen- 
activated protein (MAP) kinases and other serine/threonine kinases by IL-1β. Significantly activated were 
extracellular signal regulated kinases (ERK) 1/2, mitogen- and stress- activated protein kinase (MSK) 2, 
mitogen-activated protein kinase (MKK) 3/6, heat shock protein (HSP) 27, p38 units α, β, γ, and JNK2, 
among others, while RAC-beta serine/threonine-protein kinase B (Akt2) phosphorylation was slightly 
reduced. NaSH treatment significantly reduced the IL-1β-induced phosphorylation of MSK2, MKK.6 and 
glycogen synthase kinase (GSK) 3α/β. However, p38 MAP kinases, which were highly activated by IL-
1β, were not affected. Interestingly, NaSH treatment increased the phosphorylation of Akt1/2 by 50-60% 
and completely abolished the lining layer hyperplasia of hFLS micromasses stimulated with IL-1β. 
  
3.1.2. Hydrogen Sulfide and RA  
There have been a few recent studies reporting of the effects of H2S on in vitro models of RA. 
Kloesch et al. [56] analyzed the effects of treatment of RA hFLS with different concentrations of NaSH 
for 1 h on IL-6. They found that NaSH concentrations lower than 0.125 mM reduced constitutive IL-6 
levels and deactivated p44/42 MAPK (ERK1/2). Pre-incubation with 0.125 mM NaSH also blocked IL-
1β- induced.(5 ng/ml for 1 h) IL-6 expression. Conversely, long term exposure of hFLS to H2S (0.125 
mM NaSH for 6h) produced elevated IL-6 expression and activation of p38 MAPK, MEK1/2 and 
ERK1/2. In another study, Kloesh et al. corroborated these results using chondrocyte cell line (C-28/I2) 
[57]. As found for RA hFLS, these C-28/I2 cells also expressed high constitutive levels of IL-6 and IL-8, 
.which were decreased following stimulation with NaSH (0.125 mM for 30 min or 1 mM for 15 min). In 
agreement with their previous findings [56], pretreatment with NaSH (1 mM, for up to 60 min) of C-28/I2 
cells transiently activated the MEK/ERK pathway, the effect of which disappeared at 60 min. 
Additionally, in C-28/I2 cells stimulated with IL-1β, H2S was unable to block the degradation of IkB 
(nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor) a or the phosphorylation of 
NFkB p65.  
 
A later study confirmed the adverse effects of NaSH exposure to RA hFLS [55]. The expression of IL-
6, IL-8 and COX-2 mRNA was induced in RA hFLS for up to 6 h after 20 min of stimulation with NaSH 
concentrations above 0.5 mM. MMP3 mRNA was also upregulated in these RA-FLS. In a positive 
observation, these authors report that MMP14 and MMP2 were downregulated [55]. It is worthy of note 
that both MMP2 and its molecular regulator MMP14 are enzymes relevant to RA; both are expressed at 
elevated levels in the synovial membrane and at sites of joint destruction in RA [62-64]. As previously 
reported [57] in RA and OA hFLS, NaSH treatment at 1 mM for 1 h resulted in phosphorylation of 
ERK1/2 at 15 min after treatment. Inhibitors of MAPKs inhibited the H2S-induced expression of IL-6, IL- 
8 and COX-2 mRNA, as well as ERK1/2 activation in both cell types. 
 
Another study confirming detrimental effects of H2S on RA hFLS [58] used commercially available 
RA hFLS treated with 0.05-5 mM NaSH. Short term exposure of the cells to 2 mM NaSH for 45 min 
induced a stress response characterized by increased mRNA and protein levels of heme-oxygenase (HO)-l 
and HSP70; although the gene expression and concomitant protein levels of TNF, IL-8, IL-1β and COX-2 
were also significantly elevated. However, this NaSH induction of pro-inflammatory genes occurred 
without the involvement of NFkB transcription factor. Conversely, exposing hFLS to 2 mM NaSH 
resulted in the phosphorylation of ERK, p38 and JNK. Further experiments in hFLS with MAPK 
inhibitors demonstrated that the activation by NaSH of the COX-2 gene depends on activation of p38 and 
that of the IL-1β gene depends on ERK.  
 
Although there are some indications of beneficial results, taken collectively, available evidence from 
in vitro studies does not support any beneficial effects of H2S for RA (Fig. 1). However, because only 
NaSH was used to form H2S in these studies, it is possible that other H2S sources or concentrations might 
produce different effects.  
3.1.3. Hydrogen Sulfide and Mitochondrial Dysfunction  
Mitochondrial dysfunction has emerged as a contributing factor to the pathophysiology of both RA 
and OA. Compared to normal cells, diverse in vitro analyses of mitochondrial respiratory chain activity 
have shown decreased complexes II and III activities in OA hACs [65]. This mitochondrial dysfunction 
perhaps potentiates cytokine-induced inflammation in hFLS and hACs [22, 66] and may modulate MMPs 
expression in hACs [67], Mitochondrial dysfunction may increase ROS production in OA hACs [68]. 
GYY4137 (200 μM or 500 μM) was employed to investigate the effects of pharmacological H2S on 
cellular oxidative stress in hCH- MPC and hACs. In these cells, the mitochondrial toxicity (mitochondrial 
membrane potential collapse), the decrease in mitochondrial ATP formation and the reduction of the 
cytoplasmic accumulation of cytochrome C induced by three oxidative stimuli [H2O2, 3-
morpholinosydnonimine (SIN-1, a peroxynitrite donor) and hydroxynonenal (4-HNE)], as well as in 
CTH- or CBS-siRNA treated cells, was significantly inhibited by GYY413. Collectively, these results 
suggest a cytoprotective role against oxidative injury for H2S)in human joint cels [34].   
 
Our group has investigated the anti-oxidant properties of GYY4137 and NaSH using OA hACs and 
found that only 200 μM GYY4137 reduced mitochondrial ROS (measured by 1,2,3-dihydrorhodamine 
and flow cytrometry), in LPS-, but not IL-1β-, stimulated cells; this level had no effect on the mRNA 
expression levels of the anti-oxidant enzymes mitochondrial superoxide dismutase (SOD2) and catalase 
(CAT) [52]. However, in an ischemic/reperfusion model, increased levels of SOD2 and reduced ROS 
levels have been reported [69]. As previously mentioned, compounds that deliver H2S directly to the 
mitochondria, such as AP39, have recently been developed. To the best of our knowledge, these new 
compounds have not yet been tested on models of joint inflammatory diseases.  
3.1.4. Hydrogen Sulfide and Normal Joint Cells  
GYY4137 was also employed to investigate the effects of H2S on cellular death induced by H2O2, 
SIN-l and 4-HNE in hCH-MPC and hACs [34]. When cells were treated with D,L-propargylglycine 
(PAG, CTH inhibitor), aminooxyacetate (AOAA, CBS inhibitor) or CTH-, CBS-siRNA silencing, 
GYY4137 preserved cellular viability against all three stimuli, dependent on concentration. A time and 
concentration-dependent increase in the phosphorylation of Akt, the pro-cell survival protein, was also 
induced in hACs by GYY4137. Experiments with Akt inhibitors showed that activation of Akt was 
required for GYY4137 cytoprotection against cell death.  
 
Another in vitro study revealed that GYY4137 exerted anti-inflammatory properties on LPS-treated 
normal hFLS and hACs [40]. When cells were treated with GYY4137 previously (for 1 h prior to LPS 
addition), and subsequently (at 6 or 18 h after LPS addition) the levels of pro-inflammatory markers 
PGE2, TNF-α, IL-6 and NO were reduced. Intracellular levels of COX-2 and iNOS and NFKB activation 
in both cell types were also reduced when GYY4137 was administered 1 h prior to LPS.  
3.2. H2S and In Vivo Models of Acute Arthritis  
In addition to the in vitro studies described above, there are a few references using in vivo animal 
models. In 2008, the effects of an intra-articular injection of Na2S on acutely inflamed joints, induced by 
kaolin/carrageenan intra-articular injections, in C57B1/6 mice were examined [59]. These effects were 
evaluated by the following parameters: leukocyte recruitment and trafficking (by intravital microscopy), 
synovial blood flow (by laser Doppler perfusion imaging), and joint pain (by hindlimb incapacitance and 
von Frey hair algesiometry). While the local administration of Na2S caused a dose-dependent reduction in 
leukocyte adherence and increased leukocyte velocity, suggesting an anti-inflammatory effect, no effect 
on joint pain was observed. However, the administration of LR to alleviate carrageenan-induced synovitis 
in rat knees produced a positive effect on pain signs [60]. In this study, Wistar rats were pretreated 60 min 
prior to induction of synovitis with either a non-selective COX inhibitor (indomethacin), LR, or an 
inhibitor of endogenous H2S production (PAG). In these rodents, pre-treatments with indomethacin and 
LR significantly reduced two common signs of pain, impaired gait and secondary tactile allodynia of the 
ipsilateral bind paw. In addition, the accompanying inflammatory response, characterized by joint 
swelling, inflammatory cell infiltration and increased synovial MPO activity, was also reduced. 
Interestingly, they found that pre- treatment with LR reduced the increased concentration of IL-1β that 
bad been induced by carrageenan in the rat knee cavity, but not those of TNF-α or IL-6. H2S pre-
treatment, however, bad no effect on carragenan-induced oxidative stress markers, including NO 
production, iNOS activity and nitration of protein tyrosine residues. Also noted was that the inhibition of 
endogenous H2S with PAG enhanced synovial iNOS activity and NO production, but had no effect on 
other tested markers of inflammation.  
  
In an in vivo model of acute joint inflammation produced by complete Freund's adjuvant (CFA) in 
mice [40], GYY4137 reduced inflammation when injected 6 h after CF A treatment, but did not have a 
prophylactic effect; it actually increased joint swelling when injected 1 h prior to CFA. Those SF 
parameters evaluated that were improved with GYY4137 treatment inc1uded SF concentrations of TNF-
α, IL-1β, IL-6 and IL-8, as well as reduced MPO activity and N-acetyl-D-glucosaminidase (NAG) 
concentration. GYY4137 was also anti-inflammatory when injected 18 h after CFA treatment, though to a 
much lesser extent. Notably, the H2S concentration in CFA-injected knees was higher than that of the 
saline-injected control knees.  
3.3. H2S and Human Clinical Studies  
Finally, there are several clinical studies reporting positive outcomes when H2S is administered to 
patients with rheumatologic diseases by soaking in sulphurous thermal water. A double-blind randomized 
controlled follow-up trial (RCT) in which hand OA patients received balneotherapy with sulphurous 
water 5 days a week for 3 weeks, while the control group bathed in tap water, was performed by Kovacs 
et al. [70]. Clinical parameters evaluated included hand pain, morning stiffness in band joints, grip 
strength of both hands and the Health Assessment Questionnaire Disability Index (HAQ), the 
Australian/Canadian Hand Osteoarthritis Index (AUSCAN) Hand Osteoarthritis Index, and EuroQol 
quality of life questionnaire. At treatment termination, the experimental group showed significant 
improvement in every parameter under the scope of the study. At the end of follow-up at 6 months, the 
values for pain parameters, and the HAQ and AUSCAN assessments continued to be significantly better 
in comparison with baseline values. In another prospective, single blinded RCT [71], treatment with 
intermittent sulphur baths (a 20 min bath 2 times a week for 6 weeks) was applied to patients with 
bilateral knee OA, while the control group bathed in tap water with the same regime and temperature (35-
36°C). Significant improvement in the Lequesne index of OA severity and the Western Ontario and 
McMaster Universities Arthritis Index (WOMAC) pain and stiffness scores for up to 6 months after 
treatment, and in self-reported pain (VAS) up to one month after treatment, was seen in the treatment 
group. The control group showed improvement in the Lequesne index only up to one month after 
treatment and in pain (VAS) only at the 3-month visit. The SF-36 bodily pain score significantly 
improved in both groups.  
 
In addition, at least three recent systematic reviews [72- 74], and a Cochrane Collaboration Review 
[75], have concluded that balneotherapy with sulphurous waters might indeed offer therapeutic value in 
rheumatic diseases. In fact, the Cochrane Collaboration review found "silver evidence concerning the 
beneficial effects of mineral baths compared to no treatment." Furthermore, the most recent OARSI 
guidelines for the nonsurgical management of knee OA in- corporate balneotherapy, including sulphurous 
waters, for individuals with multiple-joint OA and relevant comorbidities [76]. However, all these 
reviews of balneotherapy with sulphurous waters also point out that available information remains 
insufficient and that additional large and well-designed controlled randomized clinical trials are needed.  
 
The mechanisms responsible for the effects of sulphurous waters on rheumatic patients are not fully 
understood. It has been suggested that the benefits are the result of a combination of several elements. 
Chemical effects are thought to play an important role, but mechanical and thermal factors also contribute 
prominently. It is believed that the chemical components present in the water, including H2S, are 
absorbed through the skin and then act at a systemic level [77, 78]. For instance, decreased lipid 
(malondialdehyde) and protein oxidation products (carbonyls and advanced oxidation protein products) 
along with increased total antioxidant capacity (TAC) were found in the plasma of healthy volunteers that 
underwent a cycle of hydropinic therapy with sulphurous drinking water, compared with controls that did 
not [79]. Similar results were obtained in OA patients subjected to sulphur baths [80] or the combination 
of sulphur based mud baths and hydropinotherapy [49]. In addition, reduced serum TNF-α and cartilage 
oligomeric matrix protein concentrations were also found and the patients reported significantly lower 
pain scores [49].  
  
CONCLUSION  
The investigation of the involvement of H2S in inflammatory joint pathologies is a rapidly expanding 
field. To date, in vitro studies using cells from OA patients have found anti- inflammatory, anti-catabolic 
and anti-oxidant properties for H2S-producing compounds. The available in vitro evidence is still 
inconclusive in the case of RA.  
 
Several in vivo animal models of acute arthritis have shown evidence of anti-inflammatory and pain 
relieving effects using NaSH, Lawesson's reagent or GYY4137 as H2S- producing reagents. New 
mitochondria-targeting H2S delivering compounds are promising new tools for investigation of the effects 
of H2S in the cellular bioenergetics known to be altered in RA and OA. The exogenous supplementation 
of H2S using sulphurous mineral water baths might also be an option to deliver H2S treatment to patients. 
Overall, although further research is needed to confirm current working hypotheses, studies suggest that 
exogenous supplementation with H2S could have therapeutic value in inflammatory joint diseases, 
particularly OA. Current knowledge suggests that investigations in this field may produce useful 
information concerning the etiology of inflammatory joint diseases, as well as possibly offering new 
therapeutic options for treatment of arthritic patients.  
LIST OF ABBREVIATIONS  
4-HNE   = Hydroxynonenal  
ACs  = Articular chondrocytes  
Akt   = Protein kinase B  
AP39   = (10-oxo-10-( 4-(3-thioxo-3H-1,2-dithiol-5yI)phenoxy)decyl) triphenyl- 
   phosphonium bromide  
AUSCAN  = Australian/Canadian Hand Osteoarthritis Index  
CAT  = Catalase  
CBS  = Cystathionine β-synthase 
CFA  = Complete Freund's adjuvant 
CH-MPC = Chondrogenically differentiated mesenchymal progenitor cells 
COX-2  = Cyclooxygenase 2 
CTH  = Cystathionine γ-lyase 
ERK  = ExtracelIular signal regulated kinases 
FGF  = Fibroblast growth factor 
FLS  = Fibroblast-like synoviocytes 
GM-CSF = Granulocyte-macropbage colony stimulating factor 
GSK  = Glycogen synthase kinase 
GYY4137 = Motpholin-4-ium-4-methoxyphenyl (morpholino) phosphinodithioate 
h  = Human origin 
H2S  = Hydrogen sulfide 
HAQ  = Health Assessment Questionnaire Disability Index 
HO  = Heme-oxygenase 
HSP  = Heat shock protein 
IL-1β  = Interleukin-1β 
IL-1R  = Interleukin-1β receptor 
iNOS  = Inducible NO synthase 
IkB  = Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor 
JNK  = c-Jun N-terminal kinases 
LPS  = Lipopolysaccharide 
LR  = Lawesson's reagent 
MAPK  = Mitogen-activated protein kinases 
MEK  = MAPK/ERK kinase 
MKK  = Mitogen-activated protein kinase kinase 
MLS  = Macrophage-like synoviocytes  
MMPs  = Matrix metalloproteninases 
MPO  = Myeloperoxidase 
MPST  = 3-Mercaptopyruvate sulfurtransferase 
MSK  = Mitogen- and stress-activated protein kinase 
NAG  = N-acetyl-D-glucosaminidase 
NFkB  = Nuclear factor kappa-light-chain-enhancer of activated B cells 
NO  = Nitric oxide 
OA  = Osteoarthritis 
PAG  = D,L-propargylglycine 
PGE2  = Prostaglandin E-2 
PKC  = Protein kinase C 
PTGES  = Microsomal prostaglandin E synthase-l 
RA  = Rheumatoid arthritis 
RANTES = Regulated on activation, normal T cell expressed and secreted 
RCT  = Randomized controlled trial 
RNS  = Reactive nitrogen species 
ROS  = Reactive oxygen species 
SF  = Synovial fluid 
SIN-I  = 3-morpholinosydnonimine 
SOD2  = Mitochondríal superoxide dismutase 
TAC  = Total antioxidant capacity 
TNF-α  = Tumor necrosis factor-α 
VAS  = Visual analogue scale 
VCAM  = Vascular ceIl adhesion molecule 
VEGF  = Vascular endothelial growth factor 
WOMAC = Western Ontario and McMaster Universities Arthritis Index 
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